Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Atossa Genetics Inc (ATOS)

Atossa Genetics Inc (ATOS)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.37 (-0.72%)
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, and The Dr. Susan Love Research...

ATOS : 1.37 (-0.72%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.37 (-0.72%)
JNJ : 140.38 (+0.59%)
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia

SAN FRANCISCO, CA / ACCESSWIRE / October 15, 2019 / Recently, Steven Quay MD, Ph.D., Founder, Chairman and CEO of Atossa Genetics Inc. (NASDAQ:), a clinical-stage biopharmaceutical company developing novel...

ATOS : 1.37 (-0.72%)
JNJ : 140.38 (+0.59%)
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported preliminary...

ATOS : 1.37 (-0.72%)
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Kyle...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Completion of Enrollment and Dosing in Phase 1 Clinical Trial of New Proprietary Modified-Release Oral Endoxifen Tablet

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that all...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.37 (-0.72%)
Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced the online...

ATOS : 1.37 (-0.72%)
Atossa Genetics Provides Information on FDA Expanded Access Policy and Requests

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today reported that patients...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that it...

ATOS : 1.37 (-0.72%)
Thinking about buying stock in Aileron Therapeutics, Atossa Genetics, NVIDIA, Seelos Therapeutics, or Xpresspa?

InvestorsObserver issues critical PriceWatch Alerts for ALRN, ATOS, NVDA, SEEL, and XSPA.

ALRN : 0.50 (+3.38%)
ATOS : 1.37 (-0.72%)
NVDA : 212.17 (+1.64%)
XSPA : 0.70 (-3.95%)
Atossa Genetics' Preliminary Phase 2 Study Achieves Primary Endpoint: Topical Endoxifen Rapidly Reduces Breast Density

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that a preliminary...

ATOS : 1.37 (-0.72%)
Atossa Genetics Announces First Quarter 2019 Financial Results and Provides Company Update

Atossa Genetics Inc. (Nasdaq:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions, today announced financial...

ATOS : 1.37 (-0.72%)
Atossa Genetics Provides Clinical Update at the 4th Annual Precision: Breast Cancer World R&D Summit

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, announced that today Steven...

ATOS : 1.37 (-0.72%)
Thinking about buying stock in Aurora Cannabis Inc., Akari Therapeutics, Atossa Genetics Inc., Boeing Co., or Reebonz Holding Ltd.?

InvestorsObserver issues critical PriceWatch Alerts for ACB, AKTX, ATOS, BA, and RBZ.

AKTX : 1.98 (unch)
ATOS : 1.37 (-0.72%)
ACBFF : 8.6900 (-12.80%)
BA : 354.09 (+2.43%)
Atossa Genetics to Present at the 4th Annual Precision: Breast Cancer World R&D Summit April 25, 2019

Atossa Genetics Inc. (NASDAQ:ATOS), a clinical-stage biopharmaceutical company developing novel therapeutics and delivery methods for breast cancer and other breast conditions, today announced that Steven...

ATOS : 1.37 (-0.72%)
New Research Coverage Highlights Thermon Group, Apogee Enterprises, National Research, Gulf Resources, Atossa Genetics, and Broadwind Energy -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Thermon Group Holdings, Inc....

NRCIA : 33.55 (+1.51%)
THR : 26.61 (+1.49%)
APOG : 38.43 (+0.39%)
NRC : 63.57 (-0.06%)
GURE : 0.54 (-1.62%)
ATOS : 1.37 (-0.72%)
BWEN : 1.63 (+4.49%)

Van Meerten Stock Picks

The 5 Best Large Caps
I wanted to find which Large Caps had the best momentum so I used Barchart to sort the S&P 500 Large Cap Index first by the highest technical buy signals, then by the most frequent number of new highs in the last month.
CCI +0.46 , AIZ +1.17 , SBAC +0.55 , SO -0.62 , WELL -0.29
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar